0 item(s)
View cart
You have no items in your shopping cart.
02
Apr
eccDNA as a Cancer Biomarker — What Researchers Need to Know
Extrachromosomal circular DNA was, for decades, an interesting molecular curiosity with limited clinical relevance. That picture has changed substantially over the past five years.
From curiosity to cancer biology
eccDNA molecules have now been linked to a range of biologically important processes: eliciting innate immune responses, mediating intercellular communication, promoting genomic heterogeneity, and functioning as molecular sponges that sequester regulatory RNAs. Perhaps most clinically significant is the finding that cell-free eccDNAs circulating in plasma and other bodily fluids may serve as diagnostic and prognostic biomarkers across multiple cancer types.
Tumor cells shed eccDNA into circulation, and those molecules carry tumor-specific sequence content that reflects the mutational and structural landscape of the primary tumor. If those signals can be reliably captured and profiled from a liquid biopsy, the implications for non-invasive diagnostics are significant.
The purification bottleneck
The challenge is that eccDNA is present at low abundance in plasma and must be distinguished from the vast background of linear cfDNA. Standard total DNA extraction does not accomplish this. Effective biomarker work requires a purification step that specifically enriches for the circular fraction.
This is the application Biofargo's cccDNA Purification Kit was designed to support. Starting from total DNA (recommended: SDS-proteinase K digestion followed by alcohol precipitation), the kit isolates circular DNA with minimal contamination from linear forms, enabling downstream profiling by sequencing or PCR-based detection.
Practical considerations
The kit recommends immediate cccDNA purification after total DNA isolation, or rapid storage at -80°C, to prevent nicking by residual DNase activity. Input DNA must be dissolved in DNase-free water or TE.
The 100-prep format (Cat# 220501) covers initial method development and moderate throughput; the extended version (Cat# 220502) includes additional solution components for a more self-contained workflow.
© Biofargo - Advanced Solutions for Circular DNA Research
Biofargo team
